Faculty Collaboration Database

Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology 2013 Jun;120(6):1278-82

Date

03/05/2013

Pubmed ID

23453513

DOI

10.1016/j.ophtha.2012.11.042

Scopus ID

2-s2.0-84878554365 (requires institutional sign-in at Scopus site)   14 Citations

Abstract

OBJECTIVE: To compare visual outcomes in phakic and pseudophakic eyes treated with monthly intravitreal ranibizumab for exudative age-related macular degeneration (AMD).

DESIGN: Meta-analysis of individual patient data from 2 phase 3 clinical trials of intravitreal ranibizumab in neovascular AMD (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration [ANCHOR], ClinicalTrials.gov number, NCT00061594; and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration [MARINA], ClinicalTrials.gov number NCT00056836).

PARTICIPANTS AND CONTROLS: A total of 1137 patients from 2 phase 3 clinical trials.

METHODS: Phakic and pseudophakic eyes were treated with monthly intravitreal ranibizumab (0.3 mg or 0.5 mg), sham injections plus verteporfin photodynamic therapy (ANCHOR), or sham injections alone (MARINA).

MAIN OUTCOME MEASURES: Mean change from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) and the proportion of patients gaining or losing 15 or more ETDRS letters.

RESULTS: After adjusting for baseline covariates, no differences were seen in mean change in VA for phakic versus pseudophakic eyes. Pseudophakic eyes were more likely to lose 15 or more letters of vision than phakic eyes at 12 months, but not at 24 months.

CONCLUSIONS: Overall, in this analysis, lens status did not demonstrate an independent influence on mean VA for eyes treated with monthly ranibizumab. It is possible that phakic eyes may be less prone to severe vision loss.

FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

Author List

Weinberg DV, Shapiro H, Ehrlich JS

Author

David V. Weinberg MD Professor in the Ophthalmology and Visual Sciences department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Clinical Trials, Phase III as Topic
Female
Humans
Intravitreal Injections
Lens, Crystalline
Male
Photochemotherapy
Photosensitizing Agents
Porphyrins
Pseudophakia
Ranibizumab
Treatment Outcome
Visual Acuity
Wet Macular Degeneration